The goal of the current study is to investigate the effect of nilotinib on drug retention in leukemia-initiating CD34+CD38− stem cells and characterize the interactions of nilotinib with ABC transporters in primary leukemic blasts. This evidence concerns the gene ABCG2 and leukemia.